At a Glance
- Company: Network Bio
- Location: Palo Alto, California
- Deal value: $50 million financing and a co-development and licensing agreement worth more than $30 million
- Focus area: AI-driven disease biology, diagnostics, biomarkers and drug development
- Next steps: Expand its academic biobank network and develop multimodal models across disease areas
What happened?
Network Bio has launched with $50 million in financing to build disease-specific AI models from human biological data. The company is combining patient-derived tissue, blood samples, molecular data and longitudinal clinical outcomes through a network of U.S. academic biobanks.
It has also signed a co-development and licensing agreement worth more than $30 million with a Fortune 100 healthcare company.
Why does it matter?
Most biomedical AI systems are trained for a single disease or application. Network Bio aims to build models that learn biological principles transferable across diseases, tissues and data types.
The approach could support earlier biomarker discovery, more precise diagnostics and improved drug development by linking molecular signals directly to patient outcomes.
Who’s behind it?
Network Bio was founded by Asad Ahmad, Raphael Potter and Hani Goodarzi. Its research network includes academic medical centres such as Mass General Brigham, the University of Pennsylvania and the University of Colorado Anschutz.
Investors include Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital.
How was it achieved?
The company is harmonising samples and data from multiple biobanks using common selection criteria and quality standards. This creates multimodal, AI-ready datasets that combine tissue and blood data with clinical histories.
Network Bio’s bio-native AI architecture is designed to reduce technical confounders and generate interpretable representations of disease biology. The platform has reported work across respiratory, ovarian and bone disease.
What’s next?
Network Bio plans to expand its life science platform and research network across immunology, metabolic, cardiovascular and autoimmune diseases. Its commercial partnership will also apply the technology to next-generation AI models for clinical applications.